drugset / Trial / NCT00683917
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
RandomizedParallel-groupSingle-blindPrevention
Summary
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Leuprolide | Other / unclassified | 3.75 mg | Intramuscular |
| Subject | Telapristone Acetate | Other / unclassified | 25 mg | — |
| Subject | Telapristone Acetate | Other / unclassified | 50 mg | — |